tiprankstipranks
Trending News
More News >
Cell Source (CLCS)
:CLCS
US Market

Cell Source (CLCS) Technical Analysis

Compare
11 Followers

Technical Sentiment

Overall Consensus
Sell
3Bullish
5Neutral
13Bearish
Technical Analysis Consensus
Buy
3Bullish
5Neutral
1Bearish
Moving Average Consensus
Strong Sell
0Bullish
0Neutral
12Bearish
Cell Source ’s (CLCS) Moving Averages Convergence Divergence (MACD) indicator is >-0.01, suggesting Cell Source is a Buy.
Cell Source ’s (CLCS) 20-Day exponential moving average is 0.28, while Cell Source ’s (CLCS) share price is $0.29, making it a Sell.
Cell Source ’s (CLCS) 50-Day exponential moving average is 0.29, while Cell Source ’s (CLCS) share price is $0.29, making it a Sell.

Cell Source (CLCS) Pivot Points

Jun 28, 2025, 06:11 AM
Name
S3
S2
S1
Pivot Points
R1
R2
R3
Classic
0.27
0.27
0.27
0.27
0.27
0.27
0.27
Fibonacci
0.27
0.27
0.27
0.27
0.27
0.27
0.27
Pivot points are a technical analysis tool used by traders to identify potential support and resistance levels in financial markets. Pivot points are calculated based on the previous day's high, low, and close prices, and are used to help traders identify levels at which the price may reverse or continue to trend.

Cell Source (CLCS) Moving Averages

Jun 28, 2025, 06:11 AM
Period
Simple
Exponential
MA5
0.27Sell
0.28Sell
MA10
0.28Sell
0.28Sell
MA20
0.29Sell
0.28Sell
MA50
0.29Sell
0.29Sell
MA100
0.32Sell
0.32Sell
MA200
0.38Sell
0.37Sell
Cell Source ’s (CLCS) 10-Day exponential moving average is 0.28, while Cell Source ’s (CLCS) share price is $0.29, making it a Sell.
Cell Source ’s (CLCS) 100-Day exponential moving average is 0.32, while Cell Source ’s (CLCS) share price is $0.29, making it a Sell.
Cell Source ’s (CLCS) stock price is $0.29 and Cell Source ’s (CLCS) 50-day simple moving average is 0.29, creating a Sell signal.
Cell Source ’s (CLCS) stock price is $0.29 and Cell Source ’s (CLCS) 100-day simple moving average is 0.32, creating a Sell signal.
Cell Source ’s (CLCS) stock price is $0.29 and Cell Source ’s (CLCS) 200-day simple moving average is 0.38, creating a Sell signal.

Cell Source (CLCS) Technical Indicators

Jun 28, 2025, 06:11 AM
Name
Value
Implied Action
RSI (14)
46.64
Neutral
STOCH (9,6)
30.91
Neutral
STOCHRSI (14)
23.97
Neutral
MACD (12,26)
>-0.01
Buy
ADX (14)
16.55
Buy
Williams %R
-79.67
Buy
CCI (14)
-48.72
Neutral
ATR (14)
0.04
-
Ultimate Oscillator
56.63
Neutral
ROC
0.00
Buy
Cell Source ’s (CLCS) Relative Strength Index (RSI) is 46.64, creating a Neutral signal.
Cell Source ’s (CLCS) Trend Strength Indicator (ADX) is 16.55, creating a Buy signal.
Cell Source ’s (CLCS) Commodity Channel Index (CCI) is -48.72, creating a Neutral signal.

FAQ

Is CLCS a Buy, Hold, or Sell?
Based on CLCS’s technical indicators, CLCS is a Sell.
    What is CLCS’s RSI (14)?
    CLCS’s RSI (14) is 46.64, which suggests CLCS is a Neutral.
      What is CLCS’s MACD?
      CLCS’s MACD is >-0.01, which suggests CLCS is a Buy.
        What is CLCS’s 5-day moving average?
        CLCS’s 5-day moving average is 0.27, which suggests CLCS is a Sell.
          What is CLCS’s 20-day moving average?
          CLCS 20-day moving average is 0.29, which suggests CLCS is a Sell.
            What is CLCS’s 50-day moving average?
            CLCS’s 50-day moving average is 0.29, which suggests CLCS is a Sell.
              What is CLCS’s 200-day moving average?
              CLCS’s 200-day moving average is 0.38, which suggests CLCS is a Sell.
                What is CLCS’s Williams % R (14)?
                CLCS’s Williams % R (14) is -79.67, which suggests CLCS is a Buy.
                  What is CLCS’s CCI (14)?
                  CLCS’s CCI (14) is -48.72, which suggests CLCS is a Neutral.
                    What am I Missing?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis